Clinical trials

  • RITUXIMAB for Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • DURVALUMAB for Unresectable melanoma | Advanced melanoma
  • DURVALUMAB for Small cell lung cancer (extensive stage) | Advanced or metastatic small-cell lung cancer
  • IKS03 for Advanced B-cell Non-Hodgkin lymphoma
  • MITOXANTRONE HYDROCHLORIDE for Acute myeloid leukemia (AML) | Chronic lymphocytic leukemia (CLL) | Myelodysplastic syndrome (MDS) | Small lymphocytic lymphoma (SLL)
  • EQUINE IMMUNOGLOBULIN F(AB')2 FRAGMENTS TARGETING SHIGA TOXIN for Hemolytic uremic syndrome|Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome
  • Daratumumab for Myalgic encephalomyelitis/Chronic fatigue syndrome
  • pembrolizumab for Advanced solid tumors
  • ZILUCOPLAN for Generalized myasthenia gravis
  • Budesonide for Eosinophilic esophagitis
  • BYON4228 (SIRPα-directed monoclonal antibody) for Relapsed/refractory CD20-positive B-cell Non-Hodgkin lymphoma
  • OXYTOCIN SYNTHETIC for Autism spectrum disorder